Research recently conducted at the Institute of Pathology in Marburg, Germany, "investigated the hypothesis that genomic patterns of mutational signatures are associated with the clinical behaviour of breast cancer...including chemotherapy response and survival." According to lead author professor Carsten Denkert, 2 mutational signatures, S3 (HRD) and S13 (APOBEC) were identified as increasing pCR rates "with neoadjuvant chemotherapy in the HR-positive subcohort."
To read more about this study, click here.
Source mentioned: Denkert C, Untch M, Benz S, et al. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. Annals of Oncology; Published online 5 January 2021. doi: 10.1016/j.annonc.2020.12.016.
No comments:
Post a Comment